Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
IL-2
|
---|---|
ln Vitro |
Human peripheral blood T cells stimulated to proliferate by phytohemagglutinin (PHA, 2.5 mg/mL) are restored by myelopeptide-2 (1 ng/mL-0.1 mg/mL; 72 h)[1]. Human T cells injured by the measles virus or HL-60 exhibit an increase in the level of reduced IL-2 production in response to myelopeptide-2 (0.1 mg/mL and 1 mg/mL; 1-3 d)[1].
|
ln Vivo |
In mice receiving short-term treatment, myelopeptide-2 (10 μg/kg; injection; for 20–50 weeks) reduces the number of spontaneous and urethane-induced lung tumors and delays the emergence of urethane-induced tumors[2].
|
Animal Protocol |
Animal/Disease Models: Male balb/c (Bagg ALBino) mouse (3-month-old) with spontaneous lung tumors[2]
Doses: 10 μg/kg; accompanied with 0.5 mg/kg Urethane or not Route of Administration: Routine injection; (1) 1 injection of MP-2 and after 7 days 3 injections of MP-2 every other day, (2) or alternating with injections of urethane (4 injections of MP-2; 3 injections of urethane+4 injections of MP-2); (3) 3 injections of MP-2 every other day or (4) alternating with injections of urethane and after 3 weeks 2 injections of MP-2 monthly with one-week interval, a total of 22 injections (25 injections of MP-2; 3 injections of urethane+ 25 injections of MP-2). For 20-50 weeks. Experimental Results: Dramatically lowered the incidence of urethane-induced lung adenomas in animals receiving 4 injections of MP-2 compared to the group receiving urethane alone or in combination with 25 injections of MP -2. |
References |
[1]. Mikhailova AA, et al. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. J Immunother. 2006 May-Jun;29(3):306-12.
[2]. Mikhailova AA, et al. Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice. Bull Exp Biol Med. 2002 Jan;133(1):68-70. |
Molecular Formula |
C41H57N7O8
|
---|---|
Molecular Weight |
775.93
|
CAS # |
137833-31-9
|
SMILES |
C(O)(=O)[C@H](CC1C2=C(C=CC=C2)NC=1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2888 mL | 6.4439 mL | 12.8878 mL | |
5 mM | 0.2578 mL | 1.2888 mL | 2.5776 mL | |
10 mM | 0.1289 mL | 0.6444 mL | 1.2888 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.